ÂÜŔňÂŇÂ×

Marc van Dijk, Ph.D. is the Chief Technology Officer at MiNK Therapeutics. He brings more than 25 years of experience leading platform development. He was previously Chief Technology Officer at Agenus. He was also Chief Technology Officer of 4-Antibody, a subsidiary of Agenus, where he oversaw the development of Retrocyte Display™, Agenus’ proprietary antibody discovery platform. In this role, Dr. van Dijk led the antibody discovery programs in the alliance with the Ludwig Institute for Cancer Research branch in New York, including the CTLA4, PD1, GITR and OX40 programs, the resulting antibodies in clinical development. Dr. van Dijk was previously Vice President, Antibody Technology at Genmab, and Director of Applied Research at Innogenetics (now Fujirebio). At Medarex and Genmab, he managed partnerships with Immunex (now Amgen), and Roche, and served as project leader on numerous discovery projects including Humax-CD20 (Arzerra™). He held a tenure track position in the Department of Immunology at the University Medical Center in Utrecht and completed his postdoctoral fellowship in Molecular Biology at the University of California, San Diego. He obtained his Ph.D. in Molecular Biology from Utrecht University.